|
A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients Clinical research trials and A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients. A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients clinical trial. Human subjects often get the best healthcare possible for their A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients  A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients
A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients
For Condition: HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: The purpose of this study is to see if giving 1592U89 to HIV-infected patients is safe and effective in lowering viral load (level of HIV in the blood) and raising the level of CD4 cells (cells of the body that help fight infection).
Details: Patients are randomized to receive one of three doses of 1592U89. During this randomized dosing phase, if a patient meets one of the following criteria, he/she is offered open-label 1592U89 (300 mg) plus zidovudine (ZDV) plus lamivudine (3TC) (or other licensed antiretrovirals according to standard practice). Criteria are based on falling CD4 counts (return to baseline on two occasions at least 1 month apart), disease progression (defined as occurrence of a new AIDS-defining event according to CDC classification excluding CD4 counts less than 200 cells/mm3), or lack of virus suppression (defined as less than 0.7log10 reduction in viral load at Week 4 with a repeat value 1 week later, more than 5000 copies/ml HIV RNA at Weeks 12, 16, 20, or 24, or 5000 copies/ml or more anytime after Week 24).
Eligibility:
Study Type: Interventional, Treatment, Double-Blind
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria:
Total Enrollment:
Location and Contact Information:
Hopital de Purpan / Service du Professeur Auvergnat
Toulouse Cedex, ,
France
Universitatsklinikurn Frankfurt
Frankfurt, ,
Germany
Universitat Erlangen
Erlangen, ,
Germany
Group Hospier Pitie-Salpetriere / Maladies Infec et Trop
Paris Cedex 13, ,
France
Groupe Hospitalier Bichat-Claude Bernard
Paris Cedex 18, ,
France
Hopital de Purpan / CHU de Rangueil / Medecine Interue
Toulouse Cedex, ,
France
Additional Information:
Study ID Numbers: 238H; CNAB2002
Study Start Date:
Record last reviewed: August 1997
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002390
Other Hiv Infections Studies:
1. A Study of Peer Education to Prevent HIV Transmission among Injection Drug Users and Their HIV Risk Contacts
2. A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated with Anti-HIV Drugs
3. Health Values and Spirituality in Veterans with HIV/AIDS
4. An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)
5. The Safety and Effectiveness of Pentamidine in the Prevention of Pneumocystis carinii Pneumonia (PCP) in Patients with AIDS Who Have Had PCP Before
Related Studies:
Other HIV Infections Clinical Trials
Other Clinical Trials
Other Frankfurt Clinical Trials
A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients
|
|
|
|
|
|
|
|
